Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

Metabolic Syndrome

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (9) ABA Receptor (2) Acetyl-CoA Carboxylase (1) ACSL Family (1) Acyltransferase (1) Akt (1) AMPK (4) Amylin Receptor (1) Androgen Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Apelin Receptor (APJ) (2) Apical Sodium-Dependent Bile Acid Transporter (5) Apoptosis (4) ATGL (1) Autophagy (2) Bacterial (2) Biochemical Assay Reagents (2) Calcium Channel (2) Cannabinoid Receptor (5) Carboxylesterase (CES) (1) Casein Kinase (1) CGRP Receptor (1) Chemerin Receptor (1) Cholinesterase (ChE) (1) Claudin (2) COX (2) DAGL (2) Dipeptidyl Peptidase (1) Drug Derivative (3) Drug Isomer (1) Drug Metabolite (2) DYRK (1) EGFR (1) Endogenous Metabolite (34) Environmental Pollutants (3) Epigenetic Reader Domain (2) ERK (3) FOXO (2) Free Fatty Acid Receptor (2) Fungal (1) G protein-coupled Bile Acid Receptor 1 (1) GLP Receptor (1) Glucocorticoid Receptor (1) Glycosidase (2) HSP (3) Interleukin Related (4) IPK Superfamily (1) Isotope-Labeled Compounds (16) JAK (1) Leukotriene Receptor (2) LPL Receptor (1) MAGL (2) Microtubule/Tubulin (2) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (2) mTOR (1) Necroptosis (2) NEKs (1) NF-κB (4) NO Synthase (2) NOD-like Receptor (NLR) (1) P-glycoprotein (2) p38 MAPK (1) PCSK9 (1) PGC-1α (1) Phosphatase (2) Phosphodiesterase (PDE) (2) Phospholipase (1) PI3K (1) Potassium Channel (1) PPAR (11) Proton Pump (2) RAR/RXR (1) Reactive Oxygen Species (ROS) (5) Reference Standards (15) RIP kinase (2) SARS-CoV (1) Sirtuin (1) STAT (1) Stearoyl-CoA Desaturase (SCD) (2) TNF Receptor (9) Toll-like Receptor (TLR) (1) TRP Channel (2) Wnt (1) Xanthine Oxidase (3) β-catenin (1)
By Research Areas:	Cancer (36) Cardiovascular Disease (18) Infection (4) Inflammation/Immunology (53) Metabolic Disease (92) Neurological Disease (11)
Oligonucleotides:	Liposomal Film-forming Agents (1) Emulsifiers (1) Cationic Lipids (1) Solubilizing Agents (1)

127

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14268

Febuxostat 10+ Cited Publications TEI 6720; TMX 67	Xanthine Oxidase	Cardiovascular Disease Metabolic Disease Cancer
Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-100560

Abscisic acid 3 Publications Verification (S)-(+)-Abscisic acid; ABA	Environmental Pollutants Endogenous Metabolite ABA Receptor Proton Pump	Metabolic Disease
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

HY-P1944

Apelin-13 Maximum Cited Publications 10 Publications Verification	Apelin Receptor (APJ)	Cardiovascular Disease Metabolic Disease
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .

HY-W018772

D-Ribose(mixture of isomers) 5 Publications Verification	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner .

HY-P1944A

Apelin-13 TFA Maximum Cited Publications 10 Publications Verification	Apelin Receptor (APJ)	Cardiovascular Disease Metabolic Disease
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .

HY-101032

RIPA-56 5+ Cited Publications	RIP kinase	Inflammation/Immunology
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC₅₀ of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome .

HY-115831

SAR247799 2 Publications Verification S1P1 agonist 3	LPL Receptor	Cardiovascular Disease
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC₅₀s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome .

HY-W012734

L-Pipecolic acid 1 Publications Verification H-HoPro-OH	Endogenous Metabolite	Metabolic Disease
L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .

HY-N3021

D-chiro-Inositol	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin	Metabolic Disease
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-145605

Vutiglabridin HSG4112	Reactive Oxygen Species (ROS) Bacterial PPAR	Metabolic Disease
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent . Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability .

HY-19762

GSK1940029 3 Publications Verification SCD inhibitor 1	Stearoyl-CoA Desaturase (SCD)	Cancer
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.

HY-15790

Elobixibat 1 Publications Verification A 3309; AZD 7806	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease Inflammation/Immunology Cancer
Elobixibat (A 3309; AZD 7806) is an orally active, bile acid transporter (IBAT) inhibitor with IC₅₀ values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to study metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .

HY-13507

Lumiracoxib 1 Publications Verification COX-189	COX	Metabolic Disease Inflammation/Immunology Cancer
Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a K_i value of 0.06?μM . Lumiracoxib acts as a nonselective NSAID with?anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .

HY-127143

Sterculic acid	Stearoyl-CoA Desaturase (SCD)	Inflammation/Immunology
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC₅₀ value of 0.9 μM .

HY-15790A

Elobixibat hydrate 1 Publications Verification A 3309 hydrate; AZD 7806 hydrate	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease Cancer
Elobixibat (A 3309; AZD 7806) hydrate is an orally active, bile acid transporter (IBAT) inhibitor with IC₅₀ values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat hydrate can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to study metabolic syndrome. Elobixibat hydrate can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .

HY-N5139

Lecithins, egg 1 Publications Verification Lecithins, egg yolk; Belovo PL 85	Cholinesterase (ChE) Angiotensin-converting Enzyme (ACE) Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Lecithins, egg (Lecithins, egg yolk; Belovo PL 85) is an orally active natural phospholipid mixture extracted from egg yolks . Lecithins, egg inhibits the activities of acetylcholinesterase (AChE) and angiotensin-converting enzyme (ACE). Lecithins, egg exhibits antibacterial, antioxidant and anti-inflammatory activities, and helps delay cellular senescence. Lecithins, egg enhances nerve conduction, improves memory and cognitive function, and exerts positive effects on delaying neurodegenerative diseases. Lecithins, egg promotes lipid absorption and alleviates diarrhea. Lecithins, egg acts as a high-efficiency drug carrier for the preparation of targeted drug delivery systems such as liposomes .

HY-W251393

S-(2-Carboxypropyl)-L-cysteine β-Isobuteine	Endogenous Metabolite	Metabolic Disease
S-(2-Carboxypropyl)-L-cysteine (β-Isobuteine) is a urine metabolite, a metabolic marker of leigh-like syndrome .

HY-150700

RLX-33	ERK	Metabolic Disease
RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC₅₀ values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome .

HY-177704

ACSL5-IN-1	ACSL Family Drug Derivative	Metabolic Disease Cancer
ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer .

HY-14268R

Febuxostat (Standard) TEI 6720 (Standard); TMX 67 (Standard)	Reference Standards Xanthine Oxidase	Cardiovascular Disease Metabolic Disease
Febuxostat (Standard) is the analytical standard of Febuxostat. This product is intended for research and analytical applications. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-W002304

(R)-5-Oxopyrrolidine-2-carboxylic acid	Drug Derivative	Metabolic Disease
(R)-5-Oxopyrrolidine-2-carboxylic acid (D-Pyroglutamic acid) is a cyclic derivative of D-glutamate. (R)-5-Oxopyrrolidine-2-carboxylic acid can be used in the research of metabolic syndrome and end-stage renal disease .

HY-W009417

Cedryl acetate	Environmental Pollutants Glycosidase	Metabolic Disease
Cedryl acetate is an orally active α-glucosidase inhibitor with an IC₅₀ of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .

HY-124314

LEI-106	MAGL DAGL	Metabolic Disease
LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a K_i of 0.8 μM for ABHD6, and an IC₅₀ of 18 nM and a K_i of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome .

HY-126359

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine SLPC; 18:0-18:2 PC	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (K_i=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .

HY-N0899

Wilforine	JAK STAT Wnt β-catenin	Inflammation/Immunology Cancer
Wilforine is an orally active JAK-STAT pathway inhibitor with immunomodulatory effects and the ability to inhibit osteoclast fusion. Wilforine disrupts lipid raft integrity, reprograms cholesterol and glycosphingolipid metabolic pathways, regulates NF-κB and the complement system, and modulates the expression of various interleukins. Wilforine also inhibits the Wnt11/β-catenin signaling pathway and suppresses the proliferation of fibroblast-like synoviocytes. Wilforine can serve as a quality and pharmacokinetic marker for Tripterygium glycoside tablets, and can be applied to research on related diseases such as rheumatoid arthritis, inflammatory osteolysis, and SAPHO syndrome .

HY-16434

DGAT1-IN-3	Acyltransferase	Metabolic Disease
DGAT1-IN-3 is a potent, selective and orally bioavailable inhibitor of DGAT-1, with IC₅₀s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. DGAT1-IN-3 could be used to research of obesity, dyslipidemia, and metabolic syndrome .

HY-163358

SLC3037 1 Publications Verification	NOD-like Receptor (NLR) NEKs	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .

HY-174140

VU0514009	Chemerin Receptor	Metabolic Disease Inflammation/Immunology
VU0514009 is a competitive chemokine-like receptor 1 (CMKLR1) antagonist (EC₅₀=2 nM). VU0514009 prevents chemerin-9-induced arrestin recruitment and receptor internalization, significantly reducing Ca ²⁺ flux response in HEK293 cells. VU0514009 is promising for research of inflammatory diseases and metabolic syndrome .

HY-100560R

Abscisic acid (Standard) (S)-(+)-Abscisic acid (Standard); ABA (Standard)	Reference Standards Endogenous Metabolite Proton Pump ABA Receptor	Metabolic Disease
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-156010

PPARγ-IN-2	PPAR	Metabolic Disease
PPARγ-IN-2 (Compound 5a) is a PPARγ inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC₅₀: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue .

HY-W018772S12

D-Ribose-d6	Isotope-Labeled Compounds Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-d₆ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-111953

SR-4559	MAGL ATGL	Metabolic Disease
SR-4559 is a α/β hydrolase domain-containing protein 5 (ABHD5) ligand. SR-4559 activates adipose triglyceride lipase (ATGL) and stimulates lipolysis by inhibiting ABHD5-PLIN interactions in adipocytes and muscle cells. SR-4559 can be used for metabolic diseases like Chanarin Dorfman syndrome research .

HY-W018772S15

D-Ribose(mixture of isomers)-13C5	Endogenous Metabolite	Inflammation/Immunology
D-Ribose(mixture of isomers)- ¹³C₅ isomers)- ¹³C₅ is the ¹³C labeled D-Ribose(mixture of isomers) . D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner .

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein PI3K Akt mTOR Apoptosis Autophagy EGFR	Metabolic Disease Cancer
Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer .

HY-E70599

Human CES2 Enzyme	Carboxylesterase (CES)	Metabolic Disease
Human CES2 Enzyme is a carboxylesterase involved in drug metabolism and lipid homeostasis. Human CES2 Enzyme hydrolyzes triglycerides, cholesteryl esters and retinyl esters to regulate lipid metabolism and energy homeostasis. Human CES2 Enzyme improves glucose tolerance and insulin sensitivity, reduces hepatic lipid accumulation, alleviates white adipose tissue steatitis, decreases plasma cholesterol levels, and reduces body weight and white adipose tissue weight. Human CES2 Enzyme can be used in the research of metabolic syndrome .

HY-W018772R

D-Ribose(mixture of isomers) (Standard)	Reference Standards Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose(mixture of isomers) (Standard) is the analytical standard of D-Ribose(mixture of isomers). This product is intended for research and analytical applications. D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner .

HY-W414548

7α,27-Dihydroxycholesterol	Others	Neurological Disease Metabolic Disease
7α,27-Dihydroxycholesterol is an oxysterol characterized by its oxidized side chains and is produced through the hydroxylation of 27-Hydroxycholesterol (27-OHC); it serves as a metabolite of interest in lipidomic analyses of various pathological conditions, including neurological diseases, Smith-Lemli-Opitz syndrome, obesity metabolic syndrome, and diabetes. Notably, levels of 7α,27-di-OHC decrease following lipopolysaccharide activation, and it also functions as a ligand for Epstein-Barr virus-induced gene 2 (EBI2). Additionally, 7α,27-di-OHC exists as a structural isomer of 7α,25-dihydroxycholesterol (7α25-OHC).

HY-W012734R

L-Pipecolic acid (Standard) H-HoPro-OH (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
L-Pipecolic acid (Standard) is an analytical standard of L-Pipecolic acid. This product is used for research and analytical applications. L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .

HY-P2819

Phosphofructokinase 1 PFK1	Phosphatase	Metabolic Disease
Phosphofructokinase 1 (PFK1) is a major regulatory enzyme targeting glycolytic pathway. Phosphofructokinase 1 catalyzes the phosphorylation of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6BP) to regulate glycolytic flux. Phosphofructokinase 1 is promising for research of cancer metabolic reprogramming (e.g., hypoxia adaptation, oxidative stress resistance) and metabolic syndromes .

HY-147086

CAY10789	Leukotriene Receptor G protein-coupled Bile Acid Receptor 1 TNF Receptor	Metabolic Disease Inflammation/Immunology
CAY10789 is a potent CysLT1R (cysteinyl leukotriene receptor 1) antagonist (IC₅₀=2.80 μM) and GPBAR1 (G-protein-coupled bile acid receptor 1) agonist (EC₅₀=3 μM). CAY10789 significantly reduces the adhesion of U937 cells to HAEC, reduces the expression of TNF-α. CAY10789 shows very promising metabolic stability and excellent pharmacokinetics. CAY10789 can be used for the research of colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .

HY-W018772S1

D-Ribose-13C	Isotope-Labeled Compounds Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose- ¹³C is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati

HY-W018772S4

D-Ribose-13C-3	Isotope-Labeled Compounds Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose- ¹³C-3 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-N7394

Galbacin (3S)-Zuonin A	AMPK	Metabolic Disease Cancer
Galbacin ((3S)-Zuonin A), the epimer of (-)-Zuonin A (HY-N7394A), is a AMPK activator. Galbacin can be isolated from Myristica fragrans (nutmeg). Galbacin stimulates AMPK enzyme in differentiated C2C12 cells. Galbacin also has anticancer activity, and inhibits the proliferation of lymphocyte and tumor cells. Galbacin prevents weight gain in diet-induced mice model. Galbacin can be used for metabolic syndrome (including obesity and type-2 diabetes) and caners research .

HY-N3021R

D-chiro-Inositol (Standard)	Reference Standards Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin	Metabolic Disease
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-123181

MK-0916	11β-HSD	Cardiovascular Disease Metabolic Disease
MK-0916 is a HSD1 inhibitor. MK-0916 produces mechanism-based activation of the hypothalamic-pituitary-adrenal axis. MK-0916 can be used in the research of type 2 diabetes and metabolic syndromes .

HY-16946

CP-610431	Acetyl-CoA Carboxylase	Metabolic Disease
CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC₅₀s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome .

HY-N7687

Caulophyllogenin	PPAR	Metabolic Disease Inflammation/Immunology
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation .

HY-P10889

CNI103	Phosphatase	Inflammation/Immunology
CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (K_D=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases .

Cat. No.	Product Name

HY-L043

Lipid Compound Library

1,266 compounds

Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies.

MCE supplies a unique collection of 1,266 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

4,703 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 4,703 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

HY-L246

Tonifying Traditional Chinese Medicine Monomer Compound Library

1,036 compounds

Tonifying traditional Chinese medicines occupy a central position in the traditional medical system, with their core value lying in the regulation of the body's functional state. Modern pharmacological studies have confirmed that these medicinal materials and their monomeric components possess multiple biological activities, including bidirectional immune regulation, anti-aging and lifespan extension, neuroprotection and cognitive enhancement, as well as hematopoietic and metabolic regulation. According to the traditional Chinese medicine theory of “strengthening the body’s resistance and consolidating the foundation”, tonifying medicines are mainly classified into four major categories: Qi-tonifying, Blood-tonifying, Yin-tonifying, and Yang-tonifying. This compound library strictly follows this classification system for compound collection.

Monomeric compounds derived from traditional Chinese medicines demonstrate excellent drug-like properties. They naturally possess structural diversity and clearly defined pharmacological activities, which help improve screening success rates and make them ideal tools for studying multi-target synergistic effects. This library contains 1,036 compounds, providing a material basis for investigating synergistic interactions among compounds (network pharmacology) and facilitating the development of multi-target therapeutic strategies for complex diseases such as cancer, neurodegenerative disorders, and metabolic syndrome.

HY-L034M

Anti-Aging Compound Library Mini

381 compounds

Research has shown that drugs targeting aging pathways demonstrate promising potential in models of age-related diseases such as Alzheimer's disease, cardiovascular diseases, metabolic syndrome, osteoarthritis, and various malignancies. This suggests that intervening in the biological processes of aging may enable synergistic prevention and treatment of multiple chronic diseases. Against the backdrop of the gradual elucidation of core aging mechanisms-including cellular senescence, telomere attrition, epigenetic dysregulation, and chronic inflammation anti-aging research has shifted from traditional phenotypic interventions toward targeting key pathways that regulate biological age.

The MCE Anti-Aging Compound Library Mini is precisely built upon this cutting-edge concept. It focuses on aging-related targets validated through genetic or functional studies, comprising 381 compounds designed to provide systematic research tools for aging biology and intervention strategy development. The library covers core mechanisms such as mTOR, SIRT, energy metabolism, clearance of senescent cells, optimization of mitochondrial function, and telomere maintenance. For each target, 1-5 compounds with clear activity and strong representativeness have been carefully selected, spanning the entire translational spectrum from preclinical tool molecules to clinically investigational drugs.

Cat. No.	Product Name	Target	Research Area

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

HY-P1944

Apelin-13 Maximum Cited Publications 10 Publications Verification	Apelin Receptor (APJ)	Cardiovascular Disease Metabolic Disease
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .

HY-P1944A

Apelin-13 TFA Maximum Cited Publications 10 Publications Verification	Apelin Receptor (APJ)	Cardiovascular Disease Metabolic Disease
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .

HY-106373

Adrenocorticotropic hormone 1 Publications Verification ACTH; Adrenocorticotrophic hormone	Androgen Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Interleukin Related TNF Receptor	Metabolic Disease Inflammation/Immunology
Adrenocorticotropic hormone (ACTH; Adrenocorticotrophic hormone) is a polypeptide tropic hormone produced by the anterior pituitary gland. Adrenocorticotropic hormone stimulates cortisol secretion from the adrenal cortex via the hypothalamic-pituitary-adrenal (HPA) axis. Adrenocorticotropic hormone regulates cortisol and androgen production. Adrenocorticotropic hormone can promote the development of spermatogenesis. Adrenocorticotropic hormone can relieve acute inflammation in gout models by inhibiting the polarization of macrophages to M1 type, inhibiting ROS and proinflammatory factor production and protecting mitochondrial function. Adrenocorticotropic hormone can be used for the researches of inflammation, endocrinology, metabolic disease, such as gout and nephrotic syndrome .

HY-106373A

Adrenocorticotropic hormone TFA 1 Publications Verification ACTH TFA; Adrenocorticotrophic hormone TFA	Androgen Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Interleukin Related TNF Receptor	Metabolic Disease Inflammation/Immunology
Adrenocorticotropic hormone (ACTH; Adrenocorticotrophic hormone) TFA is a polypeptide tropic hormone produced by the anterior pituitary gland. Adrenocorticotropic hormone TFA stimulates cortisol secretion from the adrenal cortex via the hypothalamic-pituitary-adrenal (HPA) axis. Adrenocorticotropic hormone TFA regulates cortisol and androgen production. Adrenocorticotropic hormone TFA can promote the development of spermatogenesis. Adrenocorticotropic hormone TFA can relieve acute inflammation in gout models by inhibiting the polarization of macrophages to M1 type, inhibiting ROS and proinflammatory factor production and protecting mitochondrial function. Adrenocorticotropic hormone TFA can be used for the researches of inflammation, endocrinology, metabolic disease, such as gout and nephrotic syndrome .

HY-P10889

CNI103	Phosphatase	Inflammation/Immunology
CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (K_D=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases .

HY-P4815

Prokineticin 2 Isoform 2 (human)	Endogenous Metabolite	Neurological Disease Metabolic Disease
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity .

HY-P3829

Beacon (47-73)	Peptides	Metabolic Disease
Beacon (47-73) is a C-terminal peptide fragment 47-73 of Beacon, and Beacon is a protein of 73 amino acid. Beacon (47-73) can be used for metabolic syndrome research .

HY-P11612

ATS-9R	Biochemical Assay Reagents	Metabolic Disease
ATS-9R is a peptide consisting of an adipocyte-targeting sequence and D-form 9-arginine. ATS-9R selectively transfects mature adipocytes by binding to prohibitin. ATS-9R allows an adipocyte-targeted gene delivery in vitro and in vivo. ATS-9R can be used for the development of an adipocyte-targeted gene carrier. ATS-9R can be used for the study of obesity as well as obesity-induced metabolic syndromes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14393

Emodin Maximum Cited Publications 39 Publications Verification Frangula emodin	Classification of Application Fields Polygonaceae Plants Endogenous metabolite Quinones Human Gut Microbiota Metabolites Microorganisms Rheum palmatum L. Anthraquinones Phenols Polyphenols Disease Research Fields Source Classification Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-100560

Abscisic acid 3 Publications Verification (S)-(+)-Abscisic acid; ABA	Structural Classification Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Agricultural Research Microorganisms other families Animals Terpenoids Sesquiterpenes Abscisic acid Phytohormone Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite ABA Receptor Proton Pump
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-N7075

Inulin 4 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Metabolic Disease Plants Compositae Endogenous metabolite Disease Research Fields Saccharides Sophora tomentosa L. Source Classification	Endogenous Metabolite
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; Enhancing the intestinal barrier function and reducing endotoxin translocation; Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].

HY-W018772

D-Ribose(mixture of isomers) 5 Publications Verification	Microorganisms Classification of Application Fields Endogenous metabolite Disease Research Fields Saccharides Source Classification Cancer	Endogenous Metabolite
D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner .

HY-N0515

Ophiopogonin D 1 Publications Verification	Ophiopogon japonicus (L. f.) Ker-Gawl. Cardiovascular Disease Liliaceae Classification of Application Fields Plants Disease Research Fields Steroids Source Classification	PPAR NF-κB Calcium Channel Reactive Oxygen Species (ROS) ERK
Ophiopogonin D can be isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C₂₉ steroidal glycoside. Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca ²⁺ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D can inhibit isteoclastic differentiation in RAW264.7 cells. Ophiopogonin D has protective effect as an antioxidant in H₂O₂-induced endothelial injury. Ophiopogonin D blocks ERK signaling cascades. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice. Ophiopogonin D has been used against inflammatory, metabolic and cardiovascular diseases .

HY-W012734

L-Pipecolic acid 1 Publications Verification H-HoPro-OH	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .

HY-N3021

D-chiro-Inositol	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N2468

Xylobiose 1,4-β-D-Xylobiose; 1,4-D-Xylobiose	Zea mays L. Polysaccharides Classification of Application Fields Gramineae Other Diseases Plants Disease Research Fields Saccharides Source Classification	TNF Receptor Claudin HSP
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .

HY-113166

Dodecanoylcarnitine 1 Publications Verification (-)-Lauroylcarnitine	Structural Classification Immune System Disorder Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome .

HY-111095B

D-(-)-Lactic acid sodium (R)-2-Hydroxypropionic acid sodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Drug Isomer
D-(-)-Lactic acid ((R)-2-Hydroxypropionic acid) sodium is an orally active, toxic optical isomer of Lactic acid (HY-B2227), mainly derived from overproduction by intestinal bacteria or exogenous intake. D-(-)-Lactic acid sodium can induce intoxication, characterized by severe metabolic acidosis accompanied by neurological symptoms .

HY-124529

Lunularin	Structural Classification Human Gut Microbiota Metabolites other families Conocephalum conicum (L.) Dumort. Phenols Polyphenols Plants Endogenous metabolite Source Classification	11β-HSD Endogenous Metabolite
Lunularin is an inhibitor of 11β-hydroxysteroid dehydrogenase 1, with an IC₅₀ of 45.44 μM and a K_i of 35.8 μM against human 11β-HSD1, and an IC₅₀ of 17.39 μM and a K_i of 10.31 μM against rat 11β-HSD1. Lunularin upregulates the transcription levels of Sirt1 and Hmox1 genes in the liver. Lunularin reduces food intake and body weight gain, and decreases blood glucose levels in mice fed a high-fat diet. Lunularin inhibits LPS-induced TLR4-mediated NF-κB pathway activation and nitric oxide production. Lunularin inhibits the proliferation and colony formation of renal cancer and colon cancer cells, and exhibits cancer cell-specific cytotoxicity. Lunularin binds to the steroid-binding site of human 11β-HSD1 and the steroid/NADPH-binding region of rat 11β-HSD1, but does not inhibit 11β-HSD2 or mouse 11β-HSD1. Lunularin can be used in research related to diet-induced obesity, renal cancer, colorectal cancer, inflammatory diseases and metabolic syndrome .

HY-127143

Sterculic acid	Classification of Application Fields Ketones, Aldehydes, Acids Sterculiaceae Plants Inflammation/Immunology Disease Research Fields Sterculia foetida Linn. Source Classification	Stearoyl-CoA Desaturase (SCD)
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC₅₀ value of 0.9 μM .

HY-N10319

Artepillin C	Ketones, Aldehydes, Acids Plants Compositae Artemisia capillaris Thunb. Source Classification	Epigenetic Reader Domain Necroptosis TRP Channel
Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC₅₀=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce necroptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .

HY-N15135

Arabinoxylan (Medium viscosity)	Structural Classification Polysaccharides Antibiotics Leguminosae Pisum sativum Linn Plants Saccharides Other Antibiotics Source Classification	Interleukin Related Toll-like Receptor (TLR) Fungal
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome .

HY-W251393

S-(2-Carboxypropyl)-L-cysteine β-Isobuteine	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
S-(2-Carboxypropyl)-L-cysteine (β-Isobuteine) is a urine metabolite, a metabolic marker of leigh-like syndrome .

HY-W002304

(R)-5-Oxopyrrolidine-2-carboxylic acid	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Drug Derivative
(R)-5-Oxopyrrolidine-2-carboxylic acid (D-Pyroglutamic acid) is a cyclic derivative of D-glutamate. (R)-5-Oxopyrrolidine-2-carboxylic acid can be used in the research of metabolic syndrome and end-stage renal disease .

HY-W009417

Cedryl acetate	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Taxodiaceae Metabolic Disease Plants Cunninghamia lanceolata var. konishii Disease Research Fields Source Classification	Environmental Pollutants Glycosidase
Cedryl acetate is an orally active α-glucosidase inhibitor with an IC₅₀ of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .

HY-126359

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine SLPC; 18:0-18:2 PC	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	Endogenous Metabolite
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease .

HY-N0899

Wilforine	Cardiovascular Disease Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Celastraceae Tripterygium wilfordii Hook. f. Plants Disease Research Fields Source Classification	JAK STAT Wnt β-catenin
Wilforine is an orally active JAK-STAT pathway inhibitor with immunomodulatory effects and the ability to inhibit osteoclast fusion. Wilforine disrupts lipid raft integrity, reprograms cholesterol and glycosphingolipid metabolic pathways, regulates NF-κB and the complement system, and modulates the expression of various interleukins. Wilforine also inhibits the Wnt11/β-catenin signaling pathway and suppresses the proliferation of fibroblast-like synoviocytes. Wilforine can serve as a quality and pharmacokinetic marker for Tripterygium glycoside tablets, and can be applied to research on related diseases such as rheumatoid arthritis, inflammatory osteolysis, and SAPHO syndrome .

HY-100560R

Abscisic acid (Standard) (S)-(+)-Abscisic acid (Standard); ABA (Standard)	Structural Classification Microorganisms other families Animals Terpenoids Sesquiterpenes Plants Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Proton Pump ABA Receptor
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-N6932

Voacamine	Alkaloids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Indole Alkaloids Source Classification	Cannabinoid Receptor P-glycoprotein PI3K Akt mTOR Apoptosis Autophagy EGFR
Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer .

HY-W018772R

D-Ribose(mixture of isomers) (Standard)	Structural Classification Microorganisms Endogenous metabolite Saccharides Source Classification	Reference Standards Endogenous Metabolite
D-Ribose(mixture of isomers) (Standard) is the analytical standard of D-Ribose(mixture of isomers). This product is intended for research and analytical applications. D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner .

HY-W012734R

L-Pipecolic acid (Standard) H-HoPro-OH (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
L-Pipecolic acid (Standard) is an analytical standard of L-Pipecolic acid. This product is used for research and analytical applications. L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .

HY-N7372

Licoisoflavanone	Structural Classification Flavonoids Classification of Application Fields Leguminosae Isoflavanones Other Diseases Phenols Polyphenols Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Source Classification	Apoptosis
Licoisoflavanone is an orally active isoflavane-based immunomodulator with multiple activities including antiviral, anti-inflammatory, cytoprotective and cancer cell apoptosis-inducing effects. Licoisoflavanone can be isolated from the roots and rhizomes of Glycyrrhiza uralensis Fisch. Licoisoflavanone not only enhances the body's immunity, but also effectively prevents acute respiratory distress syndrome and multiple organ damage by alleviating cytokine storm, thereby reducing the degree of inflammation. In rats, Licoisoflavanone undergoes multiple metabolic transformation processes such as glucuronidation, hydroxylation, sulfation, methylation and dehydrogenation. Licoisoflavanone has become an important candidate molecule for research on COVID-19 and related inflammatory diseases .

HY-N0515R

Ophiopogonin D (Standard)	Ophiopogon japonicus (L. f.) Ker-Gawl. Liliaceae Plants Steroids Source Classification	Reference Standards PPAR NF-κB Calcium Channel ERK Reactive Oxygen Species (ROS)
Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D can be isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside. Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D can inhibit isteoclastic differentiation in RAW264.7 cells. Ophiopogonin D has protective effect as an antioxidant in H₂O₂-induced endothelial injury. Ophiopogonin D blocks ERK signaling cascades. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice. Ophiopogonin D has been used against inflammatory, metabolic and cardiovascular diseases .

HY-N10319R

Artepillin C (Standard)	Ketones, Aldehydes, Acids Plants Compositae Artemisia capillaris Thunb. Source Classification	Reference Standards TRP Channel Necroptosis Epigenetic Reader Domain
Artepillin C (Standard) is the analytical standard of Artepillin C (HY-N10319). This product is intended for research and analytical applications. Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC₅₀=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce apoptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .

HY-N11262

Sudachitin	Structural Classification Flavonoids Flavones Rutaceae Citrus sudachi Hort. ex Shirai. Plants Source Classification	Phosphodiesterase (PDE) Sirtuin PGC-1α p38 MAPK HSP TNF Receptor NO Synthase Apoptosis
Sudachitin is an orally active compound that potently inhibits mouse PDE1C and human PDE4B, with IC₅₀ values of 5.0 μM and 15.0 μM, respectively. Sudachitin upregulates Sirt1 and PGC‑1α expression in skeletal muscle to regulate energy metabolism and promote mitochondrial biogenesis. Sudachitin improves lipid metabolism, glucose tolerance, insulin sensitivity, energy expenditure, and fatty acid β‑oxidation. Sudachitin activates p38MAPK signaling, induces HSP27 phosphorylation and caspase‑dependent apoptosis, and blocks EGF‑driven keratinocyte migration and proliferation. Sudachitin suppresses LPS‑induced TNF‑α, NO, and iNOS expression in macrophages and shows potent anti‑inflammatory activity. Sudachitin can be used for the research of metabolic syndrome, type 2 diabetes, and psoriasis. .

HY-N7394

Galbacin (3S)-Zuonin A	Natural Products Virola surinamensis (Rol. ex Rottb.) Warb. Myristicaceae Plants Source Classification	AMPK
Galbacin ((3S)-Zuonin A), the epimer of (-)-Zuonin A (HY-N7394A), is a AMPK activator. Galbacin can be isolated from Myristica fragrans (nutmeg). Galbacin stimulates AMPK enzyme in differentiated C2C12 cells. Galbacin also has anticancer activity, and inhibits the proliferation of lymphocyte and tumor cells. Galbacin prevents weight gain in diet-induced mice model. Galbacin can be used for metabolic syndrome (including obesity and type-2 diabetes) and caners research .

HY-N3021R

D-chiro-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N7687

Caulophyllogenin	Triterpenes Classification of Application Fields Leguminosae Terpenoids Acacia catechu (Linn. f.) Willd. Plants Disease Research Fields Inflammation/Immunology Source Classification	PPAR
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation .

HY-177003

SM (d18:1/15:0)	Animals Lipid Source Classification	Phospholipase
SM (d18:1/15:0) is a sphingomyelinase inhibitor. SM (d18:1/15:0) is promising for research of neurodegenerative diseases (e.g., Alzheimer's) and metabolic syndrome .

HY-W587784

Norbixin	Bixaceae Bixa orellana Linn. Ketones, Aldehydes, Acids Plants Source Classification	PPAR
Norbixin is a carotenoid that has been found in B. orellana.It binds to PPARγ in a cell-free assay (Ki = 1.15 μM) . Norbixin attenuates hyperglycemia, hyperinsulinemia, and insulin resistance, as well as decreases serum lipid levels and cardiac levels of thiobarbituric acid reactive substances (TBARS) and glutathione (GSH) in a rat model of cardio-metabolic syndrome .

HY-N2468R

Xylobiose (Standard) 1,4-β-D-Xylobiose (Standard); 1,4-D-Xylobiose (Standard)	Structural Classification Zea mays L. Polysaccharides Gramineae Plants Saccharides Source Classification	Reference Standards TNF Receptor Claudin HSP
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .

HY-N12161

3-Acetyl-11-keto-ursolic acid	Ketones, Aldehydes, Acids Rosaceae Plants Eriobotrya japonica (Thunb.) Lindl. Source Classification	Others
3-Acetyl-11-keto-ursolic acid (Compound 18) is a triterpenoid compound derived from Eriobotrya japonicaleaves. 3-Acetyl-11-keto-ursolic acid has 11B-hydroxysteroid dehydrogenase 1 (11b-HSD1) inhibitory activity. 3-Acetyl-11-keto-ursolic acid can be used for anti-diabetes research .

HY-W009417R

Cedryl acetate (Standard)	Structural Classification Natural Products Taxodiaceae Plants Cunninghamia lanceolata var. konishii Source Classification	Reference Standards Glycosidase Environmental Pollutants
Cedryl acetate (Standard) is the analytical standard of Cedryl acetate. This product is intended for research and analytical applications. Cedryl acetate is an orally active α-glucosidase inhibitor with an IC₅₀ of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .

HY-113166R

Dodecanoylcarnitine (Standard) (-)-Lauroylcarnitine (Standard)	Structural Classification Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Dodecanoylcarnitine (Standard) is the analytical standard of Dodecanoylcarnitine (HY-113166). This product is intended for research and analytical applications. Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome .

HY-N16477

Ciceritol	Structural Classification Leguminosae Cicer arietinum L. Plants Saccharides Monosaccharides Source Classification	Drug Metabolite
Ciceritol is a dietary fiber component/prebiotic targeting α-galactosidic linkage oligosaccharides. Ciceritol selectively promotes proliferation of beneficial bacteria like Bifidobacteria. Ciceritol is promising for research of gut microbiota-related diseases (e.g., irritable bowel syndrome, metabolic syndrome) .

HY-W251393R

S-(2-Carboxypropyl)-L-cysteine (Standard) β-Isobuteine (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
S-(2-Carboxypropyl)-L-cysteine (β-Isobuteine) (Standard) is the analytical standard of S-(2-Carboxypropyl)-L-cysteine (HY-W251393). This product is intended for research and analytical applications. S-(2-Carboxypropyl)-L-cysteine is a sulfur-containing amino acid derivative. S-(2-Carboxypropyl)-L-cysteine is excreted in urine within 24 hours after acute ingestion of black garlic by humans.

HY-W002304R

(R)-5-Oxopyrrolidine-2-carboxylic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Drug Derivative
(R)-5-Oxopyrrolidine-2-carboxylic acid (Standard) is the analytical standard of (R)-5-Oxopyrrolidine-2-carboxylic acid (HY-W002304). This product is intended for research and analytical applications. (R)-5-Oxopyrrolidine-2-carboxylic acid (D-Pyroglutamic acid) is a cyclic derivative of D-glutamate. (R)-5-Oxopyrrolidine-2-carboxylic acid can be used in the research of metabolic syndrome and end-stage renal disease .

Cat. No.	Product Name	Chemical Structure

HY-W018772S12

D-Ribose-d6
D-Ribose-d₆ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-W018772S15

D-Ribose(mixture of isomers)-13C5

D-Ribose(mixture of isomers)- ¹³C₅ isomers)- ¹³C₅ is the ¹³C labeled D-Ribose(mixture of isomers) . D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner .

HY-W018772S1

D-Ribose-13C
D-Ribose- ¹³C is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati

HY-W018772S4

D-Ribose-13C-3
D-Ribose- ¹³C-3 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-164236S

C22 Glucosylceramide (d18:1/22:0)-d4

C22 Glucosylceramide (d18:1/22:0)-d₄ is deuterium labeled C22 Glucosylceramide (d18:1/22:0) (HY-164236). C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields .

HY-W018772S10

D-Ribose-5,5-C-d2
D-Ribose-d₂ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-W018772S7

D-Ribose-d-1
D-Ribose-d-1 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-W018772S6

D-Ribose-d
D-Ribose-d is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gly

HY-W018772S14

D-Ribose-d5
D-Ribose-d₅ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-W018772S

D-Ribose-18O
D-Ribose- ¹⁸O is the ¹⁸O labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati

HY-W018772S9

D-Ribose-d-3
D-Ribose-d-3 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-W018772S8

D-Ribose-d-2
D-Ribose-d-2 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-W018772S5

D-Ribose-13C-4
D-Ribose- ¹³C-4 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772S2

D-Ribose-13C-1
D-Ribose- ¹³C-1 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772S3

D-Ribose-13C-2
D-Ribose- ¹³C-2 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772S16

D-Ribose-1,2-13C2

D-Ribose-1,2- ¹³C₂ is the ¹³C labled D-Ribose(mixture of isomers) (HY-W018772) . D-Ribose(mixture of isomers) is an energy enhancer，and acts as a sugar moiety of ATP，and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation，induces NF-κB inflammation in a RAGE-dependent manner .

HY-15790S

Elobixibat-d5

Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790). Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC₅₀ values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .

Cat. No.	Product Name		Classification